drugset / Trial / NCT01555242
A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.
Timeline
- Start
- 2012-08
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aneustat | Unknown | 1000 mg | Oral |
| Subject | Aneustat | Unknown | 1500 mg | Oral |
| Subject | Aneustat | Unknown | 2000 mg | Oral |
| Subject | Aneustat | Unknown | 2500 mg | Oral |